Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Pharma News

Highlights from the Week of 01st June 2026 - 08th June 2026 ( EU, Approval ) EC grants approval to Sanofi's SARCLISA SC in combination with standard-of-care regimens for the treatment of patients with multiple myeloma ( FDA, Orphan Drug, Fast Track ) TearSolutions' LACRIPEP received Orphan Drug and Fast Track designations from the FDA to treat neurotrophic keratitis ( FDA, Fast Track ) FDA grants Fast Track designation to Merakris Therapeutics' MTX-001 that treats venous leg ulcers ( FDA, Fast Track ) FDA provides Fast Track designation to Verastem Oncology's VS-7375 for the treatment of adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic NSCLC Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 01st June – 08th June in the world of pharma and healthcare!

June 9, 2026

Highlights from the week of 25th May - 01st June AbbVie ( FDA, Approval ) AbbVie's DECNUPAZ gains FDA approval to treat BPDCN, a hematologic malignancy with limited treatment options AstraZeneca ( FDA, Approval ) FDA gives approval to AstraZeneca's IMFINZI in combination with BCG induction and maintenance therapy for the treatment of adult patients with BCG-naïve, high-risk NMIBC Shionogi ( FDA, Approval ) Shionogi's XOCOVA receives FDA approval for post-exposure prophylaxis of COVID-19 in adults and adolescents 12 years and older Mannkind ( FDA, Approval ) MannKind's AFREZZA inhalation powder is now FDA approved for use in children and adolescents aged 6 years and older with type 1 and 2 diabetes All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 25th May – 01st June in the world of pharma and healthcare!

June 1, 2026

Highlights from the Week of 18th May 2026 - 25th May 2026 ( FDA, Approval ) AstraZeneca and Daiichi Sankyo gets FDA approval for its DATROWAY to treat adults with unresectable or metastatic TNBC ( FDA, Approval ) FDA approves AstraZeneca's BAXFENDY, an aldosterone synthase inhibitor, for the treatment of hypertension in combination with other antihypertensives ( FDA, Approval ) Bio-Thera and Accord BioPharma gets FDA approval for IMMGOLIS and IMMGOLIS INTRI, a biosimilar for the treatment of adults with moderately to severely active rheumatoid arthritis and ulcerative colitis ( CHMP, Positive Opinion ) Merck gets positive CHMP opinion for KEYTRUDA in combination with PADCEV as neoadjuvant treatment and as adjuvant treatment post radical cystectomy for adults with resectable MIBC Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 18th May – 25th May in the world of pharma and healthcare!

May 26, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Investor calendar

2026 RBC Capital Markets Global Healthcare Conference 2026 RBC Capital Markets Global Healthcare Conference May 19,2026 To May 20,2026 May 20 May 19 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of May 19,2026 To May 20,2026

May 18, 2026

Bank of America Securities Healthcare Conference May 12,2026 To May 14,2026 May 12 May 13 May 14 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of May 12,2026 To May 14,2026

May 11, 2026

Q1 2026 Earning Conference Call May 04,2026 To May 07,2026 May 04 May 05 May 07 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of May 04,2026 To May 07,2026

May 5, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Healthcare Insights

WORLD THALASSEMIA DAY HIDDEN NO MORE - Finding the Undiagnosed, Supporting the Unseen AN INHERITED HEMOGLOBIN DISORDER Thalassemia is a genetic condition caused by mutations in globin genes that lead to an imbalance of α- and β-globin chains, resulting in red blood cell destruction The 2026 Global Mission: To identify undiagnosed individuals and support those whose daily challenges remain unrecognized by society & healthcare systems Global Lighting Initiative "Bring To Light" movement encourages cities to illuminate iconic landmarks in red to symbolize solidarity and advocacy Alpha vs. Beta Thalassemia PREVALENCE Alpha Beta Alpha types involves deletions on chromosome 16 Beta types usually involve point mutations on chromosome 11 Minor vs. Major (TDT vs. NTDT) 1.3 M Global Cases Among them, 400,000 children are born with severe forms annually Mild Severe Minor/Trait Major/Transfusion-Dependent Often asymptomatic carriers Requires lifelong blood support for survival THALASSEMIA BELT REGIONS SYMPTOMS & COMPLICATIONS Chronic fatigue Pale skin Jaundice Shortness of breath Bone deformities Growth retardation THE TREATMENT REVOLUTION CASGEVY REBLOZYL Cell-based gene therapy Erythroid maturation agent The Danger of Iron Overload STANDARD CARE: TRANSFUSIONS & CHELATION Frequent transfusions can lead to iron accumulation, causing and organ damage Regular blood transfusions to maintain hemoglobin levels and iron chelation therapy to remove excess iron from the body Vyuhpharma® All Rights Reserved Note: This report is generated based on publicly available data

Every drop of awareness brings hope ❤️On World Thalassemia Day, we work together to create awareness on thalassemia, encourage early diagnosis and better access to care, and support patients and their families Together, we can help build a healthier and stronger future for every life affected by thalassemia

May 8, 2026

WORLD ASTHMA DAY MAY 5, 2026 BREATHE EASY , LIVE FULLY What Is Asthma? It is a chronic, non-communicable, inflammatory condition.That causes the airways in the lungs to swell, narrow, and produce extra mucus. ASTHMA CAN AFFECT ANYONE, AT ANY AGE 363M to 434M High Total Globally Approximately Prevalent in Children & Adolescents, Particularly Aged 5–9 and 10–17 Years, respectively 442L to 450L Total Mortality Low Adolescents Children 5–9 Yrs 10–17 Yrs Key Insight: Over 90% of deaths occur in low-to-middle income countries due to a lack of access to inhaled corticosteroids Low prevalence High prevalence Moderate prevalence Types of Asthma Allergic Asthma Non-Allergic Asthma Occupational Asthma Exercise-Induced Bronchoconstriction Cough-Variant Asthma Aspirin-Induced Asthma Common Tiggers Asthma Symptoms Air pollution Allergens Tobacco smoke Infection Physical activity Emotional stress Wheezing Shortness of Breath Chest Tightness Persistent Cough Key Management Strategy Microscopic View Healthy Airway Severe Asthma Airway smooth muscle: Hyperresponsiveness Constriction Thickening Early diagnosis and regular monitoring Adherence to prescribed medications Avoidance of known triggers Patient education awareness Asthma action plan Subepithelial inflammation and fibrosis Mucus hypersecretion and impaired mucus clearance Treatment Regimen Main Role Top Examples Medication Increased eosinophils and/or neutrophils in airway lumen Daily Controller (ICS) Prevents swelling/mucus Pulmicort, Arnuity, QVAR Combination (ICS+LABA) Long-term control + open airways Symbicort, Breo, Dulera AIR / MART Therapy One inhaler for daily use Symbicort (Budesonide/Formoterol) Quick Reliever (SABA) Immediate "emergency" relief Albuterol (Ventolin, ProAir) Add-on (LAMA/LTRA) Extra support for difficult symptoms Spiriva, Singulair Biologics Targeted injections for severe cases Dupixent, Tezspire, Exdensur Oral Steroids (OCS) Short-term "reset" for major flares Prednisone Bronchial Comparison Air trapped in alveoli Relaxed smooth muscles Tightened smooth muscles Wall inflamed and thickened Asthmatic airway during attack Normal airway Asthmatic airway

On World Asthma Day 2026, we stand for every breath, every life that matters.Asthma affects millions worldwide; yet, with the right awareness, early diagnosis and consistent care, it can be managed effectively.Let’s work together to create environments that support healthier lungs and better lives.

May 5, 2026

World Parkinson’s Day 2026 Substantia nigra (Dopamine producing cells) Dopamine levels in normal neuron Parkinson’s disease (PD) is a neurodegenerative disorder that predominantly affects the dopamine-producing “dopaminergic” neurons, in specific area of the brain called the substantia nigra Lewy body inclusion Diffuse α-synuclein aggregates Motor Neuron Receiving neuron Transmitting neuron Dopamine receptor Dopamine Cellular Pathology Oligomerization α-synuclein monomer Mature Lewy body inclusion α-synuclein protofibril oligomer α-synuclein fibril aggregates Autocatalytic process Dopamine levels in PD affected neuron High PD symptoms Non-motor symptoms Motor symptoms 25.2M people with PD disease globally by 2050 Depression, anxiety, cognitive impairment Low Stooped posture Masked face Back rigidity Forward tilt Flexed elbows and wrists Loss of smell Prevalence of PD in the US Hand tremor Gastrointestinal symptoms M Flexed hip and knees W Tremors in legs 1.2M (2030) Americans will be living with PD 54% 46% 80+ 60-79 40-59 Joint pain Shuffling, short stepped gait (Age 80+) Age groups Clinical symptoms and time course of PD progression Early stages PD Diagnosis Advanced stages Prodromal period Impaired balance, functioning intact Both sides affected but balance remains One side of the body is affected Constipation RBD Walking and standing difficult without help Wheelchair-bound or bed-ridden -10 0 -20 10 20 PD management Diagnosis Symptomatic Treatment No Disease-modifying therapies (DMT) approved HIGH UNMNET NEED PERSISTS MAO-B inhibitors (MAOBi): Rasagiline, Selegiline Levodopa-Carbidopa: Standard fixed dose Prodrug formulations: Foslevodopa/ Foscarbidopa MRI PET scan SNCA LRRK2 GBA Blood & CSF Biomarkers MDS-UPDRS PDQ-39 "ON/OFF" Time Deep-Brain Stimulation (DBS) DBS for stronger symptom relief Neuroimaging Assessments Genetic tests Laboratory tests Vyuhgenics®, ISO 27001 & 9001 certified Note: This report is generated based on publicly available data

This World Parkinson’s Day, we stand united to amplify awareness and drive meaningful change. Parkinson’s is more than a condition—it’s a journey that impacts millions of lives. By supporting research, innovation, and compassionate care, we move one step closer to a better future. Together, let’s turn awareness into action.

April 11, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of use

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message